A strategic plan is key to building a strong patent portfolio. If your patent is challenged, will it withstand those rigors and remain an asset, or will it become a liability?
At Finnegan, we train our professionals to draft and prosecute patent applications strategically, with the clients’ interests and instructions always at the forefront. Our attorneys also have experience with litigation and invalidation proceedings that enables them to provide the highest quality work by prosecuting applications with an eye toward enforcement as well as against challenges.
Our patent prosecution practice includes seasoned professionals as well as experienced junior team members with relatively low billing rates and often extensive technical and/or prosecution experience. The attorneys, patent agents, and technical specialists have science and/or engineering backgrounds, and many have earned advanced degrees in their technical fields and/or have industry experience. They strive to add value from the invention mining/invention disclosure stage by collaborating with the client’s scientific contributors to set boundaries and to define the scope of the developed invention. It is their intense focus to effectively communicate the achievements of our clients’ inventions during the patent prosecution process.
Finnegan professionals annually file and prosecute approximately 3,500 patent applications at the European Patent Office (EPO), the UK Intellectual Property Office (UKIPO), and the U.S. Patent and Trademark Office (USPTO). They also file under the Patent Cooperation Treaty (PCT). The technologies at issue span nearly every industry sector, including semiconductors, medical devices, chemicals, metals, pharmaceuticals, biotechnology, industrial manufacturing, robotics, consumer electronics, computer software, and business methods.
Our European, UK, and U.S. patent professionals often work side by side to provide clients with strategic and cost-efficient coordination of their patent portfolio. They provide a well-coordinated, consistent, and comprehensive global prosecution strategy that maximizes patent protection and minimizes costs associated with foreign filing and prosecution.
Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer. Those patents cover a small molecule, fruquintinib, which received approval in China.
Finnegan successfully generated patents to cover protease inhibitor Viracept®, for then startup company Agouron Pharmaceuticals, Inc. Agouron was ultimately acquired by Warner-Lambert (now part of Pfizer) based on the strength of the Viracept® patents, for $2.1 billion.
Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million. Sanofi agreed to pay $3.7 billion to acquire Principia.
Webinar
Section 102 and Prior Art: Navigating the Expanded Scope of Prior Art and AIA Exceptions
August 7, 2024
Webinar
Award/Ranking
Women in Business Law EMEA Awards 2024: Finnegan Nominated for German Firm of the Year
May 15, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.